Get started
Author

Brittney Munayirji

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
2024 · Alison Moskowitz, Gunjan L. Shah, et al. · Blood · 12
T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
2022 · Alison J. Moskowitz, Gunjan Shah, et al. · HemaSphere · 11
Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
2024 · Alexandra Dreyfuss, Nivetha Ganesan, et al. · Blood · 2
Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability
2023 · Brittney Munayirji, Niloufer Khan, et al. · Blood · 1
PDF
Neutropenic Diet Versus Liberalized Diet in Patients With Cancer: A Systematic Review and Meta-Analysis
2026 · Fares Jamal, Ayla Kouli, et al. · JCO Oncology Practice
Neutropenic diet (ND) versus liberalized diet (LD) in patients with cancer: A systematic review and meta-analysis.
2026 · Fares Jamal, Ayla Kouli, et al. · Journal of Clinical Oncology
Nanofiber-Infused Smart Hydrogels for Accelerated Re-Epithelialization in Chronic Wound Healing
2026 · Andrew Pugliese, Ryan Porter, et al. · ARC Journal of Dermatology
PDF
Investigating Subclinical Elastosis in Long-Term Steroid Use and Its Contribution to Skin Thinning
2025 · Alejandra Sataray-Rodriguez, Nicole Aust, et al. · Dermis.
Distinct Patterns of CD4+ and CD8+ T-Cell Clonal Expansion Enable Broad Clinical Responses to Pembrolizumab + GVD in Patients with Relapsed Hodgkin Lymphoma
2023 · Beatriz Wills, Jahan Rahman, et al. · Blood
PDF
Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
2022 · Beatriz Wills, Nivetha Ganesan, et al. · Blood
Works count: 10
Citation count: 26
H-index: 2
I10-index: 2
Year
Topic
Type